The HIV Vaccine Trials Network (HVTN), the NIH/NIAID Division of AIDS (DAIDS), and Janssen Vaccines and Prevention are pleased to welcome scientific study proposals involving specimens and/or study data from the Imbokodo (HVTN 705/VAC89220HPX2008) HIV vaccine clinical trial.
A study published in the Aug. 22, 2022 issue of Nature Medicine identifies a new biomarker that appears effective as a surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1, the most common type of the virus that causes AIDS.